Nivolumab bindet an den Rezeptor PD-1 auf T-Lymphozyten und verhindert so dessen abwehrhemmende Wirkung. 11. Combination therapy with nivolumab plus ipilimumab has resulted in longer overall survival than previous standard therapies in patients with melanoma8 and in those with renal-cell carcinoma.9 In a phase 1 study involving patients with NSCLC, the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with PD-L1–expressing tumors.10 Decreasing the dose and frequency of administration of ipilimumab (1 mg per kilogram of body weight every 6 weeks) when combined with nivolumab resulted in fewer adverse events than other ipilimumab regimens while maintaining improved efficacy in patients with NSCLC.10. Datenbanken für Ärzte, Cancer researchers are developing more effective ways to treat advanced melanoma, including using some drugs in combination. ); Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany (M.R. ), and Aix-Marseille University, National Center for Scientific Research, INSERM, Centre de Recherche en Cancérologie de Marseille, Assistance Publique–Hôpitaux de Marseille, Marseille (F.B.) Der Hersteller informiert. Racial Health Inequities, Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults, Case 39-2020: A 29-Month-Old Boy with Seizure and Hypocalcemia, https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf, https://www.gene.com/download/pdf/tecentriq_prescribing.pdf, https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150027c.pdf, https://www.foundationmedicine.com/genomic-testing/foundation-one-cdx, Treatment-related adverse events leading to discontinuation. A complete list of the investigators in part 1 of the CheckMate 227 trial is provided in the Supplementary Appendix, available at NEJM.org. Behandlungsbedingte unerwünschte Ereignisse traten bei 509 von 547 Patienten (93%) in der Nivolumab-plus-Ipilimumab-Gruppe sowie bei 521 von 535 Patienten (97%) in der Sunitinibgruppe auf. Although the relative benefit of nivolumab plus ipilimumab, as compared with chemotherapy, was numerically greater in patients with a PD-L1 expression level of less than 1% than in those with a PD-L1 expression level of 1% or more, this result was mostly due to variations between the PD-L1 subgroups in both the median duration of survival and in survival rates in the chemotherapy group. OPDIVO® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Opdivo 10mg/ml Lunapharm Konzentrat zur Herstellung einer Infusionslösung, Nivolumab 10 mg/ml Flüssigkonzentrat zur Infusion (Parenterale Anwendung). 15. Address reprint requests to Dr. Hellmann at the Thoracic Oncology Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 885 2nd Ave., New York, NY 10017, or at [email protected]. PD-L2 werden T-Zellreaktionen einschließlich Tumorabwehrreaktionen potenziert. Nivolumab is an anti-PD-1 drug, which is an antibody that promotes the tumor-killing effects of T-cells (white blood cells that help your body fight disease). Diese traten bei Kombination mit Ipilimumab in höheren Häufigkeiten auf als bei einer Nivolumab-Monotherapie und waren mit einer adäquaten medizinischen Behandlung meist reversibel. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The study randomised 945 treatment-naive patients with stage III or IV melanoma; 314 patients received nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg every 3 weeks for 4 doses followed by nivolumab at 3 mg/kg every 2 weeks, 316 patients received nivolumab at 3 mg/kg every 2 weeks plus ipilimumab-matched placebo, and 315 patients received ipilimumab at 3 mg/kg every 3 weeks for 4 … Analyses of all other end points were also descriptive. 4. Kowanetz M, Zou W, Shames DS, et al. Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma that is intermediate- or poor-risk in 3.3 People with untreated advanced renal cell carcinoma could be offered 1 of 4 oral tyrosine kinase inhibitors, as recommended in NICE's technology appraisal guidance on cabozantinib, pazopanib, sunitinib or tivozanib. At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab … For further information, see the summary of product characteristics. Whitehouse Station, NJ: Merck, June 2019 (package insert) (https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf). Es existieren nur begrenzt Daten hinsichtlich schwer eingeschränkter Nierenfunktion, als dass sich daraus Schlüsse für diese Population ableiten lassen. ); Matrai Gyogyintezet, Matrahaza, Hungary (I.A. Nachfolgend sind die Nebenwirkungen bei einer Monotherapie entsprechend ihrer Häufigkeit gelistet: Weitere, teils schwerwiegende, selten und sehr selten auftretende Nebenwirkungen sind hier nicht im Einzelnen aufgeführt. In patients with a PD-L1 expression level of 50% or more, the 2-year overall survival rate was 48.1% and 41.9%, respectively. Opdivo (nivolumab) is a member of the anti-PD-1 monoclonal antibodies drug class and is commonly used for Colorectal Cancer, Esophageal Carcinoma, Head and Neck Cancer, and others. Nivolumab (Opdivo®) + Ipilimumab (Yervoy®) Immunotherapy for advanced melanoma activates your immune system to attack the cancer cells. A decision-analytic … Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. Deshalb sollten Patienten mindestens bis 5 Monate nach der letzten Dosis engmaschig überwacht werden. J Thorac Oncol 2017;12:Suppl:S321-S322. * NA denotes not applicable because all the patients in this group had a PD-L1 expression level of 1 or more. 22. ¶ The number of mutations (mut) was determined with the use of the FoundationOne CDx assay. Vor fast 1 Woche habe ich die 2. von 4 geplanten Infusionen erhalten. Das progressionsfreie Überleben (PFS) nahm von 2,9 Monaten unter Ipilimumab auf 6,9 Monate unter Nivolumab und auf 11,5 Monate unter Nivolumab plus Ipilimumab zu. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Prices start at $12,990.29 On the performance-status evaluation of the Eastern Cooperative Oncology Group (ECOG), a score of 0 indicates that the patient is fully active, and a score of 1 indicates that the patient is restricted in physically strenuous activity but ambulatory. This report is based on the final analysis of overall survival with nivolumab plus ipilimumab, as compared with chemotherapy, in patients with a PD-L1 expression level of 1% or more, as of the database lock of July 2, 2019. ‡ On the performance-status evaluation of the Eastern Cooperative Oncology Group (ECOG), a score of 0 indicates that the patient is fully active, and a score of 1 indicates that the patient is restricted in physically strenuous activity but ambulatory. ); Sotiria General Hospital, National and Kapodistrian University of Athens, Athens (K.S. 02.12.2020 - CheckMate 238-Studie: Im Vergleich zu Ipilimumab profitieren Patienten mit reseziertem Melanom im Stadium IIIB-C oder IV langfristig von Nivolumab. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. You have ipilimumab and nivolumab through a drip into your bloodstream (intravenously). Although this trial was not powered to compare the two regimens, our findings show better efficacy with nivolumab plus ipilimumab than with nivolumab monotherapy within the same trial. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; … Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer N Engl J Med. Nivolumab mit Ipilimumab: Wirkstoffkombination hat Zusatznutzen bei fortgeschrittenem Nierenzellkarzinom. NEW! Über 10.000 Inhaltsstoffe mit Wirkstoff-Informationen und Präparate-Zuordnung. 28. Sun JX, He Y, Sanford E, et al. Studies of single-agent immunotherapy regimens have shown minimal benefit. Information, resources, and support needed to approach rotations - and life as a resident. * 2. 2. Studien zur Untersuchung der Fertilität wurden nicht durchgeführt. N Engl J Med 2015;373:23-34. Cell 2018;175(4):998.e20-1013.e20. J Clin Oncol 2019;37:992-1000. We also evaluated the benefit of nivolumab plus ipilimumab, as compared with nivolumab plus chemotherapy, in patients with a PD-L1 expression level of less than 1% (Fig. Adverse events were assessed by the investigator and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Of the 1189 patients who had a PD-L1 expression level of 1% or more, 396 were assigned to receive nivolumab plus ipilimumab, 396 to receive nivolumab monotherapy, and 397 to receive chemotherapy. Sie schloss nur Patienten ohne BRAF V600-Mutation … Ovvero che il 54% dei pazienti ha avuto gravi ripercussioni collaterali del tipo “pausa ad effetto” , ha detto Suzanne Topalian, direttore del programma melanoma presso la Johns Hopkins Kimmel Cancer Center di Baltimora e ricercatore leader nell’immunoterapia. N Engl J Med 2018;378:2093-2104. These treatments include monotherapy blockade of programmed death 1 (PD-1) in patients with tumors that express programmed death ligand 1 (PD-L1) or such treatment in combination with chemotherapy, regardless of tumor PD-L1 expression.1-7 Still, current therapies extend long-term survival in only a minority of patients with NSCLC. Hellmann MD, Rizvi NA, Goldman JW, et al. 21. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. You have ipilimumab over 30 or 90 minutes depending on your cancer type. Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab … Also shown are the 1-year and 2-year rates of survival in the two groups. CTLA-4 has very high structural homology to the costi-mulatory molecule CD28, and it could also bind B7 molecules present on antigen-presenting cells (APCs) with much higher affinity and avidity than CD28 (Schildberg et al., 2016; Sharma and Allison, 2015a). Prices start at $12,990.29 The hazard ratio for death of 0.79 (97.72% confidence interval, 0.65 to 0.96) (Table S2) provides an overall estimate of benefit and should be interpreted in the context of the shape of the curves, which are characterized by transient initial survival benefit with chemotherapy, followed by long-term benefit with nivolumab plus ipilimumab. Key Points Question Is pembrolizumab-axitinib cost-effective as first-line treatment of advanced renal cell carcinoma compared with nivolumab-ipilimumab, the other preferred first-line regimen? Compare prices, print coupons and get savings tips for Nivolumab (Opdivo) and other Melanoma drugs at CVS, Walgreens, and other pharmacies. An ECOG score of 2 or more was reported in 4 patients in the group with PD-L1 expression of 1% or more and in 6 patients in the overall population; data were missing for 3 patients and 2 patients in the two populations, respectively. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. J Clin Oncol 2018;36:633-641. Daher muss unter Abwägung des Nutzens des Stillens für das Kind und des Nutzens der Behandlung für die Mutter eine Entscheidung darüber getroffen werden, ob das Stillen oder die Behandlung mit Nivolumab unterbrochen werden soll. However, toxicities made up a much larger proportion of the cost of care for nivolumab and pembrolizumab. Die The institutional review board or independent ethics committee at each center approved the trial. S6 and S7 and Table S9). Darüber hinaus wurde die adjuvante Behandlung mit Nivolumab gut vertragen: Behandlungsbedingte unerwünschte Ereignisse vom Grad 3 oder 4 traten bei 14,4 % der Patienten auf und Therapieabbrüche aufgrund von Toxizität erfolgten bei 9,7 %. If the proportional assumption was not met, hazard ratios were still reported to provide a conventional estimate of overall average effect and supplemented by median and landmark estimates. Duale Blockade von PD-1 und CTLA-4-vermittelten Signalwegen führte in genidentischen Maus­modellen zu synergistischer Tumoraktivität. 25. The most common treatment-related select adverse events of any grade with a potential immunologic cause in the group that received nivolumab plus ipilimumab were skin reactions (in 34.0% of the patients) and endocrine events (in 23.8%) (Table S10). † Nivolumab monotherapy was evaluated only in the primary-analysis population involving patients with a PD-L1 (programmed death ligand 1) tumor expression of 1% or more. Nivolumab dove comprarlo What Is A Dove - What Is A Dove . Im Rahmen dieser doppelblinden, randomisierten Phase … For example, the overall survival benefit for nivolumab plus ipilimumab, as compared with chemotherapy, in patients with a high PD-L1 expression level (≥50%) and a high tumor mutational burden was similar to that in patients with a low PD-L1 expression level (<1%) and a low tumor mutational burden (Figure 3 and Fig. Paz-Ares L, Luft A, Vicente D, et al. The results suggest that the superior efficacy of nivolumab plus ipilimumab over sunitinib was maintained in intermediate-risk or poor-risk and intention-to-treat patients with extended follow-up, and show the long-term benefits of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma across all risk categories. Die Auswirkung von Nivolumab auf die männliche oder weibliche Fertilität ist unbekannt. La combinazione di due molecole immuno-oncologiche, nivolumab e ipilimumab, riduce il rischio di progressione della malattia del 20%, di morte del 13% e … Nivolumab ist bei erwachsenen Patienten zur Behandlung folgender Tumorarten indiziert: Nivolumab ist ein humaner Immunoglobulin-G4-(IgG4) monoklonaler Antikörper, der an den Programmierten Zelltod 1-(PD-1)-Rezeptor bindet und die Interaktion des Rezeptors mit seinen  Liganden PD-L1 und PD-L2 verhindert. The contribution of ipilimumab was evaluated in an analysis of nivolumab plus ipilimumab, as compared with nivolumab monotherapy, in patients with a PD-L1 expression level of 1% or more (Fig. In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. Damit wurde erstmals eine immunonkologische Kombinationstherapie für Patienten mit dieser Art der Tumorerkrankung in der Europäischen Union zugelassen. Overall Survival in Patients with a Tumor PD-L1 Expression Level of 1% or More and in Prespecified Subgroups. An overall survival benefit with nivolumab plus ipilimumab, as compared with chemotherapy, was observed regardless of the subgroup of PD-L1 expression level. All the patients had received no previous chemotherapy. The hazard ratio for the group with a PD-L1 expression level of 1% or more is shown with a 97.72% confidence interval; stratified hazard ratios for all the patients and those with a PD-L1 expression level of 1% or more are shown. ); Limoges University Hospital, Limoges (A.V. Among the patients with a PD-L1 expression level of less than 1%, the rate of progression-free survival was significantly higher with nivolumab plus chemotherapy than with chemotherapy alone (10.5% vs. 4.6% at 2 years; hazard ratio for disease progression or death, 0.73; 97.72% CI, 0.56 to 0.95; P=0.007). Costo del sovrappeso in pazienti in terapia con ipilimumab per melanoma avanzato in tre centri oncologici italiani NICOLETTA JANNITTI U.O.C. S8). In patients with a PD-L1 expression level of 1% or more, the rate of overall survival at 2 years was 40.0% with nivolumab plus ipilimumab and 36.2% with nivolumab monotherapy. Of the 550 patients with a PD-L1 expression level of less than 1%, 187 were assigned to receive nivolumab plus ipilimumab, 177 to receive nivolumab plus chemotherapy, and 186 to receive chemotherapy. † For nivolumab plus ipilimumab, these events included treatment-related adverse events leading to the discontinuation of ipilimumab alone or the discontinuation of both nivolumab and ipilimumab; the discontinuation of nivolumab alone was not permitted. This benefit was observed across most subgroups (Fig. 10. The authorized source of trusted medical research and education for the Chinese-language medical community. Tumor mutation burden as a biomarker in resected non-small-cell lung cancer. Nivolumab (Handelsname Opdivo) ist ein Checkpoint-Inhibitor, der als Wirkstoff gegen verschiedene Tumoren eingesetzt wird.Es handelt sich um einen menschlichen (vollständig humanen) monoklonalen Antikörper, der an den PD-1-Rezeptor auf T-Zellen bindet und die Wechselwirkung mit dem eigentlich hier bindenden PD1-Rezeptor-Ligand verhindert. Chicago – Eine Erstlinientherapie mit Nivolumab in Monotherapie oder in Kombination mit Ipilimumab ist bei Patienten mit metastasiertem Melanom signifikant wirksamer als eine Monotherapie mit Ipilimumab. We reported the primary end point of progression-free survival with nivolumab plus ipilimumab, as compared with chemotherapy, in patients with a high tumor mutational burden (≥10 mutations per megabase) previously.11 Here, we report the primary end point of overall survival with nivolumab plus ipilimumab, as compared with chemotherapy, in patients with a tumor PD-L1 expression level of 1% or more. Gebärfähige Frauen sollten während der Behandlung und bis mindestens 5 Monate nach der letzten Gabe von Nivolumab wirksame Verhütungsmethoden anwenden. Über 110.000 Arzneimittel und Medizinprodukte mit Anwendungs- und Fachinformationen. Crossover between the treatment groups during the trial was not permitted. In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). A subgroup … Substantial progress has been made in the first-line treatment of patients with advanced non–small-cell lung cancer (NSCLC) without driver alterations that can be targeted. DOI: 10.1056/NEJMoa1910231, Tap into groundbreaking research and clinically relevant insights. Derzeit überleben weniger als 50 Prozent der Patienten mit metastasiertem Nierenzellkarzi… In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). The main reason for exclusion was not meeting the trial criteria. Am J Clin Oncol 1982;5:649-655. Ergebnisse wurden in einem Peer-Review-Journal publiziert [3]. • 6 semanas después de la última dosis de la combinación de nivolumab e ipilimumab si se administra 480 mg cada 4 semanas. Cell 2017;168(3):487.e15-502.e15. ); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A. All treatment-related adverse events and serious adverse events were reported during the time between the first dose of a trial treatment and 30 days after the last dose. Reck M, Rodríguez-Abreu D, Robinson AG, et al. The safety of nivolumab plus ipilimumab has been improved in patients with NSCLC with the use of a lower dose and frequency of administration of ipilimumab, as was suggested in the phase 1 dose-finding study.10, In addition, the duration of overall survival was longer with nivolumab plus ipilimumab than with chemotherapy in all the trial patients, including in those with a PD-L1 expression level of less than 1%, a population for whom anti–PD-1 monotherapy has been insufficient. Prespecified analyses that were not part of the statistical testing hierarchy are descriptive (Table S1). One of the sponsors (Bristol-Myers Squibb) and a steering committee designed the trial and analyzed the data, with the participation of all the authors. The median duration of response was 23.2 months (95% CI, 15.2 to 32.2) with nivolumab plus ipilimumab and 15.5 months (95% CI, 12.7 to 23.5) with nivolumab monotherapy among the patients with a PD-L1 expression level of 1% or more; among those with a PD-L1 expression level of 50% or more, the median duration of response was 31.8 months (95% CI, 18.7 to not reached) and 17.5 months (95% CI, 13.5 to 31.0), respectively. However, the between-group difference did not meet the nominal significance level of 0.023 (hazard ratio for death, 0.78; 97.72% CI, 0.60 to 1.02, P=0.035) (Fig. Table 2. N Engl J Med 2016;375:1823-1833. r The phase II CheckMate 069 study showed similar efficacy and toxicity for patients receiving combination ipilumumab/nivolumab and ipilimumab monotherapy respectively. r The phase II CheckMate 069 study showed similar efficacy and toxicity for patients receiving combination ipilumumab/nivolumab and ipilimumab monotherapy respectively. Wei SC, Duffy CR, Allison JP. The most trusted, influential source of new medical knowledge and clinical best practices in the world. Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.e15134 Background: We use a decision analytic model to project the effectiveness and cost burden of microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic … Durch ein malignes Melanom entstandene Metastasen werden bei mir (nach 10 x Kopfbestrahlung) seit Kurzem mit Nivolumab/Ipilimumab behandelt. Der Hersteller informiert. If a hierarchical end point was not met, the remaining end points in the hierarchy were considered to be descriptive only. ‡ Treatment-related deaths in the group that received nivolumab plus ipilimumab were from pneumonitis (in 4 patients) and from shock, myocarditis, acute tubular necrosis, and cardiac tamponade (in 1 patient each). Overall Survival in Patients with a Tumor PD-L1 Expression Level of Less Than 1% and in All the Patients. Die Europäische Kommission hat der Kombination von Nivolumab (Opdivo®) und Ipilimumab (Yervoy®) als Erstlinientherapie für Patienten mit fortgeschrittenem Nierenzellkarzinom (RCC) mit intermediärem oder ungünstigem Risikoprofil die Zulassung erteilt. Exploratory analysis of additional PD-L1 expression thresholds that are currently used for selection of anti–PD-1 monotherapy showed more variable benefit (Figure 3). 6 Wochen nach der letzten Dosis der Kombination von Nivolumab und Ipilimumab, wenn 480 mg alle 4 Wochen gegeben werden. 27. Among the patients who had disease progression during the trial, subsequent systemic therapy was administered in 43.6% of the patients who had received nivolumab plus ipilimumab and in 55.8% of those who had received chemotherapy; immunotherapy was administered in 42.4% of those in the chemotherapy group. In einer Populationsanalyse betrug die mittlere geometrische Clearance (CL) 7,9 ml/h, die terminale Halbwertzeit 25 Tage und die durchschnittliche Exposition im Steady-State von Nivolumab (3 mg/kg Körpergewicht alle 2 Wochen) 86,6 µg/ml. Nivolumab ist ein humaner Immunglobulin G4 (IgG4) monoklonaler Antikörper, der zur Therapie von fortgeschrittenen Melanomen, nicht-kleinzelligem Lungenkarzinom, Nierenzellkarzinom, klassischem Hodgkin-Lymphom, Plattenepithelkarzinom des Kopf-Hals-Bereiches sowie des Urothelkarzinoms zugelassen ist. Among the 679 patients (58.2%) in whom the tumor mutational burden was evaluated, a similar degree of overall survival benefit was observed in patients who received nivolumab plus ipilimumab, regardless of whether they had a high tumor mutational burden or a low tumor mutational burden (≥10 vs. <10 mutations per megabase, respectively), despite the previous observation of improved progression-free survival in patients with a high tumor mutational burden.11. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. Concise summaries and expert physician commentary that busy clinicians need to enhance patient care. The primary end point reported here is overall survival with nivolumab plus ipilimumab, as compared with chemotherapy, in patients with a PD-L1 expression level of 1% or more. List item. (Details are provided in the Methods section in the Supplementary Appendix.) Nivolumab in combination with ipilimumab is a potential cost-effective treatment option for patients with intermediate or poor risk renal cell carcinoma (RCC), according to a study presented at the virtual 2020 ESMO Annual Congress. 17.04.2018 Nivolumab plus Ipilimumab war mit einem besseren Überleben als Chemotherapie bei NSCLC mit hoher Tumormutationsbelastung verbunden laut einer im New England Journal of Medicine veröffentlichten Studie. Stay connected to what's important in medical research and clinical practice, Subscribe to the most trusted and influential source ofmedical knowledge. We thank the patients and their families for making this trial possible; the investigators and clinical trial teams who participated in the trial; Suresh Alaparthy, Judith Bushong, and Christopher Coira of Bristol-Myers Squibb for their contributions as protocol managers of the trial; Joseph Szustakowski, Han Chang, and George Green for their analyses of the tumor mutational burden; Foundation Medicine for the collaborative development of the FoundationOne CDx assay; Dako for the collaborative development of the PD-L1 IHC 28-8 pharmDx assay; and Namiko Abe and Laura Yee of Caudex for their assistance in the preparation of the manuscript, including contributions to the first draft.